There is a temptation, when writing about the Indian CDMO landscape, to write a promotional brief. This is not that. If you're a European or North American buyer evaluating your first Indian supplier, or reviewing an existing one, you want a candid map of the space — including the parts where Indian CDMOs (ours included) still can't compete.
This piece covers current capacity, which regulatory credentials matter to which buyers, where China+1 has actually delivered, and the structural gaps that remain. It's written from the operator's chair, not the analyst's desk.
The state of Indian CDMO capacity
Between 2022 and 2025, Indian CDMOs collectively added significant API and intermediates capacity. Public expansions across the top-tier players alone represent hundreds of tonnes of new annualised commercial supply, plus commensurate analytical capacity.
That capacity is real, but it's unevenly distributed. Small-molecule API capacity is well-served; peptide chemistry, high-potency APIs, and complex generics like inhaled dosage forms remain under-served relative to demand. Buyers looking for those categories often still find themselves calling European or Japanese CDMOs first.
Regulatory credentials — who cares about what
Not every regulatory credential means the same thing to every buyer. The buyers who make this mistake — treating WHO-GMP, MHRA, USDMF, and CEP as interchangeable — end up with the wrong supplier for their market.
- European specialty pharma
- MHRA and CEP first. WHO-GMP as a baseline. USDMF is a nice-to-have but not the gating credential.
- North American generics
- USDMF first, mandatory. WHO-GMP baseline. MHRA useful for tri-continent supply strategies.
- APAC buyers (Southeast Asia, ANZ)
- WHO-GMP typically sufficient. Some markets (Australia, Singapore) may require additional TGA / HSA registrations.
- LATAM buyers
- WHO-GMP baseline. Market-specific registrations (ANVISA for Brazil, COFEPRIS for Mexico) are the gating item.
- MENA / Africa
- WHO-GMP is often sufficient. GCC harmonisation is improving but market-specific work still required.
The USDMF gap
A US Drug Master File (USDMF) is a substantial commitment — full manufacturing details, impurity profiles, and stability data submitted to FDA and maintained thereafter. Many Indian CDMOs have USDMFs on the top 20-30 molecules they manufacture but not on their long-tail portfolio. For North American generics buyers, that gap matters.
China+1 — where it delivered and where it didn't
The China+1 supply strategy has been a real macro tailwind for Indian CDMOs, but the win has been uneven. In our experience it delivered clearly in three areas — and less clearly in a fourth.
- Small-molecule API commercial supply — Indian sites captured meaningful share as European and US buyers de-risked from Chinese suppliers.
- Route scouting and development services — engagements have grown, with buyers investing to build a second qualified route ahead of geopolitical risk.
- Analytical testing — cross-validation and second-source method transfer engagements have grown steadily.
- Complex generics and biologics — the mainland-to-India shift has been slower here because the underlying capability gap is real.
Structural gaps that still exist
Peptide and oligonucleotide chemistry
There are a small number of Indian sites capable of solid-phase peptide synthesis at commercial scale, but the depth of the market is thin compared to European or US sites. Oligonucleotide capacity is even thinner. Buyers with peptide or oligo programmes typically start their supplier search elsewhere.
High-potency APIs (HPAPI)
Dedicated containment infrastructure (OEB 4-5) exists at a handful of Indian sites but is not widely available. For sponsors with HPAPI programmes, especially oncology, the qualified vendor list is short.
Complex dosage forms
Inhalation, ophthalmics, complex parenterals — these remain a European and Japanese stronghold. Indian sites have made progress, but the regulatory and equipment complexity means the gap will take another decade to close fully.
Where Operant Scientific fits (and doesn't)
We manufacture small-molecule APIs and intermediates. We do route scouting, technology transfer, analytical testing, and R&D as a portfolio. We are not a peptide site, not an HPAPI site, and not a complex-generics site. Buyers evaluating us for those categories should call someone else — we'll happily refer, because starting with a mismatched supplier wastes everyone's time.
“The Indian CDMOs that win the next five years are the ones honest about what they can't do. That honesty is a form of respect for the buyer's time.”
Common misconceptions European buyers hold
- 'Indian CDMO' means monolithic. It does not. The variance in quality within India is much larger than the variance between India and Europe on average.
- 'Cheaper = worse'. Sometimes true, often not. A well-run Indian site can be cost-competitive because of labour economics, not because of skimping on quality.
- 'MHRA-approved covers everything'. MHRA is UK, not EU. Post-Brexit, EU sponsors still need the EMA framework — MHRA alignment is helpful but not equivalent.
- 'DMF filed = DMF approved'. Filed means submitted; approved means reviewed and accepted. Ask which one.
A framework for evaluating CDMO positioning
A useful mental model for evaluating an Indian CDMO is to ask two orthogonal questions: what is their regulatory posture, and what is their pricing posture? A regulatory-first / cost-second CDMO looks and sounds very different from a cost-first / regulatory-adequate one. Both exist. Neither is inherently wrong. Match to your programme's risk profile.
What buyers should be looking for
Three things, in order: a supplier whose regulatory record you can verify independently; a supplier who is candid about what they can and can't manufacture; and a supplier whose director is answerable when something goes wrong. Cost matters, but not until those three are settled.
If you'd like to compare notes on your own supplier landscape, send a two-line brief. We'll answer as far as we can and — as promised in the article — tell you honestly when we're not the right fit.